🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsCompounded sema dosing calculator — vial concentration reference

Compounded sema dosing calculator — vial concentration reference

KevinCompounds Thu, Jun 4, 2026 at 11:36 PM 9 replies 367 viewsPage 1 of 2
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Jun 4, 2026 at 11:36 PM#1

Writing this once so I can stop repeating it across threads. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

The condition it depends on

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

What I am trying to establish is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. I would rather have one careful answer than five confident ones.

— KevinCompounds · corrections welcome and will be edited into this post with credit
37 7jennifer_SEA, tyler_CSCS, VanRx_Mike and 34 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Jun 5, 2026 at 12:09 AM#2
KevinCompounds said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

KevinCompounds has the substance of this right. The condition it depends on is worth stating. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

36 6PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 33 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jun 5, 2026 at 12:42 AM#3
KevinCompounds said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

I read this differently from KevinCompounds, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

35 5AussieAnna, BethLabQueen, ChrisMacros and 32 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Jun 5, 2026 at 1:15 AM#4

This one has a reasonably settled answer, so here it is. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Jun 5, 2026 at 4:15 AM
34 4TinaHashiRN, robert_kc, dan_philly and 31 others
Reply Quote Save Share Report
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Jun 5, 2026 at 4:20 AM#5
Dr.ObesityMed said:
They are two different exemptions from the same federal requirements and they buy different things.

Agreed, and it is worth saying that rounding to the nearest whole unit is usually acceptable at maintenance doses and is not acceptable at the bottom of a ladder, where one unit can be a fifth of the intended dose.

33 3TomTeleRx, DoseLogDan, SleepFixSam and 30 others
Reply Quote Save Share Report

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register